AlphaMark Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

AlphaMark Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-400	Closed	-$52K	–	624
2019 Q4	$52K	Hold	400	–	–	0.02%	196
2019 Q3	$31K	Hold	400	–	–	0.01%	234
2019 Q2	$41K	Hold	400	–	–	0.02%	213
2019 Q1	$29K	Hold	400	–	–	0.01%	233
2018 Q4	$17K	Hold	400	–	–	0.01%	262
2018 Q3	$19K	Sell	400 -250	-38%	-$13.9K	0.01%	292
2018 Q2	$32K	Hold	650	–	–	0.01%	259
2018 Q1	$20K	Sell	650 -600	-48%	-$16.7K	0.01%	288
2017 Q4	$23K	Buy	1,250 +250	+25%	+$3.88K	0.01%	271
2017 Q3	$12K	Buy	+1,000	New	+$5.79K	0.01%	330

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AlphaMark Advisors's MRTX Position: Q1 2020 in Review

AlphaMark Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2020, closing a stake of 400 shares — an estimated $52K sold.

AlphaMark Advisors first reported a position in MRTX in Q3 2017 and held it in 10 quarters. The position peaked at $52K in Q4 2019. 173 funds tracked by Wall St. Rank hold MRTX as of Q1 2020.

AlphaMark Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
AlphaMark Advisors sold 400 Mirati Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $52K.
AlphaMark Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2017 and held it in 10 quarters.
AlphaMark Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $52K in Q4 2019.
173 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2020.

Based on AlphaMark Advisors's 13F filing for Q1 2020, filed 24 Apr 2020.